Thermoinactivation of poliovirus involves both RNA and protein components, with pirodavir protecting specifically against the protein component.
Answers are grounded in this paper and cite their sources.
Pirodavir may stabilize poliovirus capsids against heat; leaves open translation to vaccine stability or antiviral use pending in vivo studies.
Heating the Sabin strains of poliovirus at 42 to 45 degrees C caused inactivation, loss of native antigen, and release of the viral RNA (vRNA). The loss of virion infectivity exceeded the loss of vRNA infectivity (as measured by transfection) by roughly 2 log10. Pirodavir inhibited the loss of native antigen and RNA release and reduced the loss of virion infectivity to the same level as the loss of vRNA infectivity. Thermoinactivation thus involves an RNA and a protein component, and pirodavir protected only against the latter.
No takes yet. Share an insight, caveat, or question.
Rombaut et al. (1994) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: